HYOU1

Across TCGA pan-cancer cohorts, HYOU1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated HYOU1 data layer compared with 28 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher HYOU1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated HYOU1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, LUAD, and GBM are the cancer types where HYOU1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	II,III,IV	0.875	0.687	.005	18	view →
LUAD	OS	Median	II,III,IV	1.000	0.433	.005	11	view →
GBM	DFS	Quartile	All	0.292	0.535	.024	5	view →
HNSC	DFS	Median	IV	1.000	0.413	.033	3	view →
CCRCC	OS	Median	All	0.782	0.899	.018	2	view →
LSCC	DFS	Quartile	II,III,IV	0.770	1.000	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

HYOU1–PDAC (DFS)

Open the PDAC breakdown →